 |
4-[[[4-(4-Chlorophenoxy)phenyl]sulfonyl]-methyl] tetrahydro-N-hydroxy-2H-pyran-4-carboxamide |
|---|---|
| Trade Name | |
| Orphan Indication | Prophylaxis of organ rejection in patients receiving allogeneic liver transplants |
| USA Market Approval | USA |
| USA Designation Date | 2008-06-18 00:00:00 |
| Sponsor | Conatus Pharmaceuticals, Inc.;4365 Executive Drive;San Diego, California, 92121 |
